article thumbnail

Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc

Fierce Pharma

. | Ahead of an advisory committee meeting slated for Friday, the FDA unleashed damning briefing documents calling into question the effectiveness and safety of Intercept’s rare liver disease drug Ocaliva.

FDA 236
article thumbnail

Staying abreast of regulations with NGS?based viral safety for faster, safer and more ethical lot release of our vaccines

European Pharmaceutical Review

How does that impact the safety of the biologics? Safety is key to the development of any medicine, but the safety considerations linked to bioproduction are more complex because biologics are more sophisticated medicines than small molecules. London: European Medicines Agency; 2016 [cited May 2022]. References.

Ethics 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Report: Nurse Understaffing Is Becoming More Deadly for Patients

MedCity News

The percentage of respondents who know of a patient death being caused by nurses being assigned too many patients nearly doubled in the past seven years — from 22% in 2016 to 42% in 2023.

Patients 118
article thumbnail

First AI-generated small molecule drug enters Phase II trial

European Pharmaceutical Review

Initiating Phase II trials for an AI-generated drug The Phase II study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 12-week oral INS018_055 dosage in subjects with the rare lung disease idiopathic pulmonary fibrosis (IPF). Patients will be divided into four parallel cohorts.

article thumbnail

Bayer unit BrainVectis cleared to start Huntington gene therapy trial

pharmaphorum

In June, uniQure reported 12-month data with AMT-130 that backed its safety – an important consideration for AAV-based gene therapies in light of recent safety signals – but has yet to report any efficacy data. “Importantly, BV-101 does not affect the levels of normal huntingtin protein in cells,” she added.

Safety 105
article thumbnail

Will Novartis provide new oral option for chronic hives?

European Pharmaceutical Review

While injectable biologic therapies are an effective option for CSU that is uncontrolled by these drugs, less than 20 percent of patients worldwide are treated with them, according to a 2016 British Journal of Dermatology paper and research shared by Novartis. The post Will Novartis provide new oral option for chronic hives?

Safety 94
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. But over time, trends in what evidence is most available and therefore most used, change.

Medicine 116